Advanced Cell Technology (ACTC) Advancing Phase I/II Trials

One of the leaders in volume daily for penny stocks, Advanced Cell Technology, Inc. (OTC: ACTC), a regenerative medicine working with stem cells, looks forward to conducting  Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD) after the Wills Eye Institute in Philadelphia received institutional review board (IRB) approval. SMD is a ...

Continue Reading →
0

ACTC Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial

Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Aberdeen Royal Infirmary, the largest of the Grampian University Hospitals in Scotland, has been confirmed as a site for its Phase 1/2 human clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal ...

Continue Reading →
0

ACTC, Advanced Cell Technology Insider Transactions

On Wednesday, January 25, 2012, Advanced Cell Technology, Inc. (OTCBB: ACTC) Chief Science Officer Robert Lanza filed SEC Form 4, as required for insider trading, indicating that he sold 7.7 million shares for $1.5 million, ending with 26.0 million shares after that sale.

http://www.sec.gov/Archives/edgar/data/1140098/000114420412003966/xslF345X03/v300304_4.xml

Continue Reading →

0

ACTC: Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation

Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of an additional patient in its Phase 1/2 trial for Stargardt’s macular dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

The patient was treated on Tuesday (Jan. 24) by Steven Schwartz, M.D., Ahmanson Professor of ...

Continue Reading →
0

Update: ACTC Advanced Cell Technology Stem Cell Research

“Be fearful when others are greedy, and be greedy when others are fearful.” – Warren Buffett

Advanced Cell Technology, Inc. (OTCBB:ACTC), announced via Businesswire today that Phase 1/2 clinical data published in The Lancet as an early online publication demonstrate the safety of ACT’s human embryonic ...

Continue Reading →
0

Stock To Watch: Advanced Cell Technology, Inc. ACTC

 

 

Advanced Cell Technology, Inc. (OTCBB: ACTC)

Advanced Cell Technology, Inc. is a biotechnology company. Millions of people globally depend on ACTC’s development of cellular therapies for the treatment of diseases and conditions. To bring patient-specific therapies from the laboratory to the patient, ACTC applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine.

Continue Reading →

0